{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:20:33Z","timestamp":1786119633313,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Autoimmune thyroid disease and thyroid dysfunction are common in adults receiving interferon (IFN)-based treatment for chronic hepatitis C (CHC). Few data are available in children with CHC. This study is aimed to evaluate the appearance and timing of thyroid dysfunction and antithyroid autoimmunity in children with CHC treated with pegylated IFN-\u03b1-2b and ribavirin (RBV).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Sixty-one otherwise healthy children with CHC, 3\u201317 years of age, infected perinatally and treatment na\u00efve, receiving therapy with pegylated IFN-\u03b1-2b and RBV and 183 age- and sex-matched controls were included in a multicenter, prospective, case-control study. Thyroid-stimulating hormone, free thyroxine, antithyroglobulin antibodies and antithyroid peroxidase antibodies were assessed before, during and 24 weeks after the end of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      From baseline to the end of treatment, subclinical hypothyroidism and autoimmune thyroiditis were diagnosed in 17 of 61 (27.94%) and in 4 of 61 (6.6%) of the children treated, respectively, and in 5 of 183 (2.7%) and in none of the controls (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001, relative risk: 10.2, 95% confidence interval: 3.9\u201326.5;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.03, relative risk: 26.8, 95% confidence interval: 1.5\u2013489.1, respectively). Twenty-four weeks after the end of treatment, subclinical hypothyroidism persisted in only 4 of 61 (6.6%). Autoimmune thyroiditis persisted in 3 of 4 (75%) of the cases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Subclinical hypothyroidism is common in children with CHC receiving treatment with pegylated IFN-\u03b1-2b and RBV, but in most cases is transient. Autoimmune thyroiditis, which is less common, generally persists after treatment completion. Thyroid function should be carefully monitored in patients presenting with antithyroid autoantibodies and thyroid dysfunction during and after pegylated IFN-\u03b1\u2013based treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000001791","type":"journal-article","created":{"date-parts":[[2017,9,26]],"date-time":"2017-09-26T14:12:09Z","timestamp":1506435129000},"page":"287-291","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["Transient Hypothyroidism and Autoimmune Thyroiditis in Children With Chronic Hepatitis C Treated With Pegylated-interferon-\u03b1-2b and Ribavirin"],"prefix":"10.1097","volume":"37","author":[{"given":"Daniele","family":"Serranti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Indolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Nebbia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Cananzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"D\u2019Antiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Stagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Azzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Resti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Italian Study Group for Treatment of Chronic Hepatitis C in Children","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260107","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.gene.2015.04.087","article-title":"IFNA2: the prototypic human alpha interferon.","volume":"567","author":"Paul","year":"2015","journal-title":"Gene"},{"key":"R2-20260107","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.gtc.2015.07.011","article-title":"Hepatitis C: issues in children.","volume":"44","author":"Lee","year":"2015","journal-title":"Gastroenterol Clin North Am"},{"key":"R3-20260107","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/cid\/cis1031","article-title":"Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis.","volume":"56","author":"Druyts","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R4-20260107","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.4254\/wjh.v7.i8.1074","article-title":"Autoantibodies in chronic hepatitis C: a clinical perspective.","volume":"7","author":"Narciso-Schiavon","year":"2015","journal-title":"World J Hepatol"},{"key":"R5-20260107","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/MPG.0b013e3182774cae","article-title":"Autoantibodies and autoimmune disease during treatment of children with chronic hepatitis C.","volume":"56","author":"Molleston","year":"2013","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R6-20260107","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4254\/wjh.v8.i2.83","article-title":"Hepatitis C virus infection and thyroid autoimmune disorders: a model of interactions between the host and the environment.","volume":"8","author":"Pastore","year":"2016","journal-title":"World J Hepatol"},{"key":"R7-20260107","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1089\/jir.2016.0007","article-title":"Thyroid dysfunction in chronic hepatitis C patients treated with the combined pegylated interferon-ribavirin therapy.","volume":"36","author":"Hamza","year":"2016","journal-title":"J Interferon Cytokine Res"},{"key":"R8-20260107","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3904\/kjim.2015.30.6.792","article-title":"Incidence of and risk factors for thyroid dysfunction during peginterferon \u03b1 and ribavirin treatment in patients with chronic hepatitis C.","volume":"30","author":"Hwang","year":"2015","journal-title":"Korean J Intern Med"},{"key":"R9-20260107","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1590\/S1413-86702008000200009","article-title":"Thyroid dysfunction in hepatitis C individuals treated with interferon-alpha and ribavirin\u2013a review.","volume":"12","author":"Andrade","year":"2008","journal-title":"Braz J Infect Dis"},{"key":"R10-20260107","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2265.2007.03009.x","article-title":"Thyroid function and anti-thyroid autoantibodies in untreated children with vertically acquired chronic hepatitis C virus infection.","volume":"68","author":"Indolfi","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R11-20260107","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/hep.20661","article-title":"Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C.","volume":"41","author":"Wirth","year":"2005","journal-title":"Hepatology"},{"key":"R12-20260107","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/INF.0b013e318159836c","article-title":"Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection.","volume":"27","author":"Jara","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"R13-20260107","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jhep.2010.01.016","article-title":"High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.","volume":"52","author":"Wirth","year":"2010","journal-title":"J Hepatol"},{"key":"R14-20260107","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jhep.2010.01.028","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents.","volume":"52","author":"Sokal","year":"2010","journal-title":"J Hepatol"},{"key":"R15-20260107","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/MCG.0b013e31802dd2f6","article-title":"Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C.","volume":"41","author":"Baker","year":"2007","journal-title":"J Clin Gastroenterol"},{"key":"R16-20260107","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/MEG.0b013e32832a4e97","article-title":"Peginterferon alpha-2b and ribavirin for the treatment of chronic hepatitis C in Japanese pediatric and young adult patients: a survey of the Japan Society of Pediatric Hepatology.","volume":"21","author":"Tajiri","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R17-20260107","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1053\/j.gastro.2010.10.047","article-title":"The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C.","volume":"140","author":"Schwarz","year":"2011","journal-title":"Gastroenterology"},{"key":"R18-20260107","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1097\/INF.0000000000001325","article-title":"Kinetic of virologic response to pegylated interferon and ribavirin in children with chronic hepatitis C predicts the effect of treatment.","volume":"35","author":"Indolfi","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R19-20260107","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1590-8658(03)00217-2","article-title":"Guidelines for the screening and follow-up of infants born to anti-HCV positive mothers.","volume":"35","author":"Resti","year":"2003","journal-title":"Dig Liver Dis"},{"key":"R20-20260107","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MPG.0b013e3181f6f09c","article-title":"Guidance for clinical trials for children and adolescents with chronic hepatitis C.","volume":"52","author":"Wirth","year":"2011","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R21-20260107","doi-asserted-by":"crossref","first-page":"804870","DOI":"10.1155\/2014\/804870","article-title":"Increased incidence of thyroid dysfunction and autoimmunity in patients with vernal keratoconjunctivitis.","volume":"2014","author":"Stagi","year":"2014","journal-title":"Int J Endocrinol"},{"key":"R22-20260107","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1365-2265.2005.02365.x","article-title":"Thyroid function and morphology in patients affected by Williams syndrome.","volume":"63","author":"Stagi","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R23-20260107","first-page":"277","article-title":"Thyroid function, autoimmune thyroiditis and coeliac disease in juvenile connective tissue diseases.","volume":"23","author":"Stagi","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"R24-20260107","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jama.291.2.228","article-title":"Subclinical thyroid disease: scientific review and guidelines for diagnosis and management.","volume":"291","author":"Surks","year":"2004","journal-title":"JAMA"},{"key":"R25-20260107","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/rheumatology\/keh531","article-title":"Thyroid function, autoimmune thyroiditis and coeliac disease in juvenile idiopathic arthritis.","volume":"44","author":"Stagi","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"1 suppl","key":"R26-20260107","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/j.jhep.2016.07.007","article-title":"Second generation direct-acting antivirals - Do we expect major improvements?","volume":"65","author":"Feld","year":"2016","journal-title":"J Hepatol"},{"key":"R27-20260107","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/hep.28995","article-title":"The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12 to 17 years old with hepatitis C virus genotype 1 infection.","volume":"66","author":"Balistreri","year":"2017","journal-title":"Hepatology"},{"key":"R29-20260107","doi-asserted-by":"crossref","first-page":"15965","DOI":"10.3748\/wjg.v20.i43.15965","article-title":"New treatments for chronic hepatitis C: an overview for paediatricians.","volume":"20","author":"Serranti","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R30-20260107","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B.","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"R31-20260107","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection.","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"R32-20260107","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jhep.2013.05.016","article-title":"Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition.","volume":"59","author":"Sokal","year":"2013","journal-title":"J Hepatol"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006454-201804000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:45:34Z","timestamp":1786041934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006454-201804000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001791","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}